Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). Patient-reported outcomes. PROGRAMME.and.ABSTRACTS. Improved quality of life.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

MAY 30, 2023

A new 2023 study published in BMJ Supportive & Palliative Care suggests that cannabis could be the answer millions of cancer patients have been looking for. of patients experience pain after curative treatment, while 66.4% of patients with advanced or metastatic cancer suffer from pain. Interestingly, 72.5%

Medicine 98

Medicine Treatment Patients Data 98

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA has received adverse event reports involving delta-8 THC-containing products. brownies, gummies).

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. In 2018, ProCon.org has estimated well over 3.5M

Events 48

Events THC Chronic Pain Sleep 48

TheAnswerPage

MAY 16, 2021

Some cancer patients use medical marijuana to treat various cancer-associated ailments. According to one study involving 96 cancer patients receiving supportive cancer care, the data support the safety and effectiveness of medical marijuana as a complementary option for improving pain control, appetite and quality of life for cancer patients.

Safety 52

Safety Data Patients Events 52

TheAnswerPage

DECEMBER 5, 2020

Some cancer patients use medical marijuana to treat various cancer-associated ailments. According to one study involving 96 cancer patients receiving supportive cancer care, the data support the safety and effectiveness of medical marijuana as a complementary option for improving pain control, appetite and quality of life for cancer patients.

Data 52

Data Patients Safety Events 52

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

The Joint Blog

JANUARY 21, 2020

Marijuana use is associated with subjective benefits in patients with Tourette Syndrome (TS), according to a new study published in the journal Cannabis and Cannabinoid Research. This study was designed to further investigate efficacy and safety of CBM in GTS and specifically compare effects of different CBM.

Patients 29

Patients Marijuana Data Treatment 29

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

TheAnswerPage

JUNE 27, 2020

Some cancer patients use medical marijuana to treat various cancer-associated ailments. According to one study involving 96 cancer patients receiving supportive cancer care, the data support the safety and effectiveness of medical marijuana as a complementary option for improving pain control, appetite and quality of life for cancer patients.

Data 52

Data Patients Safety Events 52

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

The Joint Blog

APRIL 21, 2020

For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. There is moderate-quality evidence that chronic and acute administration of CBD can improve psychotic symptoms in schizophrenia patients.”

Clinical Trials 52

Clinical Trials CBD Safety Patients 52

Cannabis Law Report

NOVEMBER 24, 2019

Building the bridge between brands and the marketplace through testing and the importance of good data. These events, amongst other drivers, have shown the obvious need to regulate product safety in CBD and THC products in a holistic and standardized way.

Business 95

Business Data Wellness and Beauty Safety 95

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

The Cannigma

OCTOBER 21, 2021

Still, many patients report that cannabis helps them to feel more in control of their symptoms, leading to important questions. While there has been little systematic research on using cannabis for ADHD, many patients with the condition report positive effects from using cannabis. Can cannabis help with ADHD?

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

The Joint Blog

JANUARY 3, 2020

.” This study was designed “to further investigate efficacy and safety of CBM in GTS and specifically compare effects of different CBM.” ” All these patients were asked to complete an online survey (second study part) to receive more detailed data about treatment with CBM. .”

Data 49

Data Treatment Marijuana Patients 49

Peninsula Alternative Health

JUNE 12, 2023

This agency will build upon the existing medical cannabis program regulations and ensure health, safety, and security within the industry. Patients will still be able to obtain medical cannabis from licensed dispensaries, and individuals aged 18 or older can register to participate in the program. Can I apply for a cannabis license?

Legislation 52

Legislation Packaging Edibles Concentrates 52

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JUNE 16, 2021

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols. Lobo brings a highly experienced and specialized team of technology experts in the fields of genetics, diagnostics, data and analytics, as well as a fully operational 5,000 sq. Vancouver, British Columbia–(Newsfile Corp.

Research and Development 105

Research and Development Data Conditions Events 105

Peninsula Alternative Health

JUNE 12, 2023

This agency will build upon the existing medical cannabis program regulations and ensure health, safety, and security within the industry. Patients will still be able to obtain medical cannabis from licensed dispensaries, and individuals aged 18 or older can register to participate in the program. Can I apply for a cannabis license?

Legislation 52

Legislation Packaging Edibles Concentrates 52

SpeedWeed

AUGUST 13, 2021

Safety also played a role in Holistic Industries’ decision to convert its indoor facilities to LEDs. When you increase temperature, it’s all a chain reaction of events,” Denney says. The post Texas Cancer Patients, Those With PTSD Gear Up For Medical Cannabis Access appeared first on SpeedWeed. ” View original article.

Access 52

Access Patients Banking Cultivation 52

Cannabis Law Report

JANUARY 23, 2022

Events like these afford us a glimpse into the future of research and medicine in this field. GVHD affects a significant portion of transplant patients, anywhere between 30% and 70% of patients depending on how closely the donor’s tissue matches with the patient. and 13.4%, respectively. Implications.

Research and Development 52

Research and Development Wellness and Beauty Patients CBD 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

SEPTEMBER 23, 2021

The major concerns noted were adverse events following consumption (many from inadvertent intoxication), marketing to and use by minors, and the potential presence of harmful by-products and unsafe manufacturing practices. The FDA has received adverse event reports involving delta-8 THC-containing products. CDC Health Alert.

THC 52

THC Concentrates Pets DEA 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. COMP360 psilocybin therapy has now been given to 233 patients, exceeding 216 target. On track to report top-line data by end of 2021. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Data To Support Regulatory Filings in the United States. The study will take place in Canada with a CTA filing and enrollment of the first patient anticipated by Q2 of 2022. BERWYN, Pa.–(BUSINESS Christopher M. Chipman, CPA. Chief Financial Officer.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Healer

JUNE 28, 2019

Beyond decreasing the intensity of pain, many patients report that cannabis changes the nature of the pain, making it more bearable and less distracting. Many patients report positive mood, relaxation, laughter, social comfort, time distortion, and the intensification of ordinary experiences (e.g. Abstract: Medical Study .

Cannabinoids 52

Cannabinoids THC Therapy Patients 52

Cannabis Law Report

JUNE 27, 2019

The Cannabis Control Commission voted Tuesday to delay consideration of event licenses for another few months. To the extent that home delivery to patients has been ongoing, there may already be security in place that goes above and beyond our regulations, and to my knowledge there haven’t been incidents,” Title said.

Marijuana 49

Marijuana Recreational Data Consumption 49

Cannabis Law Report

DECEMBER 9, 2021

Johnson recently reported his interim results at Microdose’s Psychedelic Medicine Business Event, from his current smoking cessation study, utilizing a single macro-dose of psilocybin. Preclinical data on numerous sets of Mydecine’s novel compounds are showing significant improvements compared to the first generation of drugs.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JANUARY 13, 2020

We are proud of the positive impact this medicine has already had on thousands of patients and believe that this past year provides a compelling foundation for continued success in 2020,” said Justin Gover, GW’s Chief Executive Officer. “Our fourth quarter and full year results for 2019 reflect an exceptional launch year for Epidiolex.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Greenspoon Marder Cannabis Law Group Blog

OCTOBER 8, 2019

The Center for Disease Control (CDC), the federal agency that is on the front lines for any threat to public health, works closely with FDA and state health departments to gather data and then communicates risk to the public. Clusters of unrelated sick people who purchased at the same retail outlet or attended the same event.

Vaping 64

Vaping THC Supply Chain Food 64

Cannabis Law Report

NOVEMBER 26, 2021

Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. dollars in thousands (except for share and per share data). . . Topline results are expected in Q1 2022. Financial Results. September 30, . .

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52